-
EP3836922
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3836922
| EP3836922 - USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 05.07.2024 Database last updated on 18.01.2025 | |
| Former | Grant of patent is intended Status updated on 06.03.2024 | ||
| Former | Request for examination was made Status updated on 21.05.2021 | ||
| Former | The international publication has been made Status updated on 24.02.2020 | Most recent event Tooltip | 17.01.2025 | Lapse of the patent in a contracting state | published on 19.02.2025 [2025/08] | Applicant(s) | For all designated states Biohaven Therapeutics Ltd. 215 Church Street New Haven, CT 06510 / US | [2021/25] | Inventor(s) | 01 /
CORIC, Vladimir 215 Church Street New Haven, Connecticut 06510 / US | [2021/25] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2021/25] | Application number, filing date | 19849456.9 | 15.08.2019 | [2021/25] | WO2019US46709 | Priority number, date | US201862764864P | 16.08.2018 Original published format: US 201862764864 P | [2021/25] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020037152 | Date: | 20.02.2020 | Language: | EN | [2020/08] | Type: | A1 Application with search report | No.: | EP3836922 | Date: | 23.06.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.02.2020 takes the place of the publication of the European patent application. | [2021/25] | Type: | B1 Patent specification | No.: | EP3836922 | Date: | 07.08.2024 | Language: | EN | [2024/32] | Search report(s) | International search report - published on: | US | 20.02.2020 | (Supplementary) European search report - dispatched on: | EP | 05.04.2022 | Classification | IPC: | A61K31/428, A61P25/22, A61P25/24, A61K9/20 | [2022/18] | CPC: |
A61K31/428 (EP,IL,KR,US);
A61K47/64 (US);
A61K9/0056 (KR,US);
A61K9/006 (EP);
A61K9/2018 (KR);
A61K9/2063 (KR);
A61K9/2072 (US);
A61P25/22 (EP,IL,KR,US);
A61P25/24 (EP,IL);
A61P25/28 (KR)
(-)
|
| Former IPC [2021/25] | A61K31/428, A61P25/22, A61P25/24 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/25]
| Extension states | BA | 05.03.2021 | ME | 05.03.2021 | Validation states | MD | 05.03.2021 | Title | German: | VERWENDUNG VON RILUZOL-ORALEN DESINFEKTIONSMITTELTABLETTEN ZUR BEHANDLUNG VON KRANKHEITEN | [2021/25] | English: | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | [2021/25] | French: | UTILISATION DE COMPRIMÉS ORODISPERSIBLES À BASE DE RILUZOLE POUR LE TRAITEMENT DE MALADIES | [2021/25] | Entry into regional phase | 05.03.2021 | National basic fee paid | 05.03.2021 | Search fee paid | 05.03.2021 | Designation fee(s) paid | 05.03.2021 | Examination fee paid | Examination procedure | 05.03.2021 | Examination requested [2021/25] | 15.07.2022 | Amendment by applicant (claims and/or description) | 07.03.2024 | Communication of intention to grant the patent | 03.07.2024 | Fee for grant paid | 03.07.2024 | Fee for publishing/printing paid | 03.07.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 13.08.2021 | Renewal fee patent year 03 | 18.07.2022 | Renewal fee patent year 04 | 05.07.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | PL | 07.08.2024 | NO | 07.11.2024 | GR | 08.11.2024 | [2025/08] | Documents cited: | Search | [Y]WO2016081466 (BIOHAVEN PHARM HOLDING CO LTD [US]); | [Y]WO2016140879 (BIOHAVEN PHARM HOLDING CO LTD [US]); | International search | [Y]CA2507551 (ALK ABELLO AS [DK]); | [Y]US2008260823 (DILLAHA LARRY [US]); | [YA]US9434704 (KANDULA MAHESH [IN]); | [Y]US2017360775 (CORIC VLADIMIR [US], et al); | [Y]US2018037557 (WROBEL JAY EDWARD [US], et al); | [YA]US2018214395 (MANFREDI PAOLO L [US], et al); | by applicant | GB1548022 | US9192580 | US2016019787 | WO2015US61106 | WO2015US61114 | WO2016US19773 |